A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
A phase 3 trial of Tarlatamab, Durvalumab, Carboplatin in small-cell lung cancer, run by Amgen, active and no longer recruiting.
Overview
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) is a phase 3 interventional study registered as NCT07005128 by Amgen, with 350 participants enrolled, started 2025-08-18 and due to reach its primary completion in 2029-01-04. Interventions recorded: Tarlatamab, Durvalumab, Carboplatin, Etoposide. Conditions listed: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy of AZD2811 + Durvalumab in ES-SCLC
Shares Etoposide, Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialDeLLphi-305
Shares Tarlatamab, Durvalumab, Small-cell lung cancer.